CALGARY, April 30, 2015 /CNW/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that Julie Cherrington will be leaving the Company, effective April 29, 2015. Donald McCaffrey, Chairman of Zenith's Board of Directors, will assume the role as Interim President and Chief Executive Officer until a permanent replacement is appointed.
Mr. McCaffrey is pleased to host a conference call and webcast to update investors on corporate developments and upcoming milestones. The conference call and webcast will occur on Wednesday, May 13, 2015 at 11 am MDT / 1pm EDT.
Details for the conference call and webcast are as follows:
Dial in numbers:
Canada & USA Toll Free call: 1 800 319 4610
Outside of Canada & USA call: +1 604 638 5340
Link to webcast: http://services.choruscall.ca/links/zenith150506.html
About Zenith
Zenith Epigenetics Corp. is a biotechnology company developing best-in-class bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders in targeted populations with significant unmet medical need. The Company's epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Zenith's goal is to become a leading epigenetic company translating bromodomain biology into impactful therapies. Zenith's lead product is a pan selective BET inhibitor being developed for hematological malignancies and solid tumors. Zenith is targeting the second half of 2015 to file an IND for hematological malignancies and solid tumors. To learn more, please visit us at www.zenithepigenetics.com.
SOURCE Zenith Epigenetics Corp.
